Ablynx's AbbVie-Partnered Lupus Candidate Hits End Of Road
Executive Summary
Ablynx's IL-6 inhibitor has reached the end of the road in lupus; failure of the Phase II STEADY trial is unlikely to affect the biotech's acquisition deal with Sanofi but its development partner AbbVie is expected to dump the drug.
You may also be interested in...
Deal Watch: Amazon Moves Into Rx Services With Acquisition Of PillPack
Celgene makes play into RNA-expression correction via neuroscience partnership and equity investment with Skyhawk. Novartis’ Sandoz agreed to commercialize Adamis’ Symjepi, a competitor to EpiPen, in the US.
Novo Outbid As Sanofi Agrees €3.9bn Ablynx Acquisition
Sanofi is to acquire Belgian nanobody developer Ablynx in an all-cash deal worth €3.9bn, 50% higher than the spurned bid by Novo Nordisk.
AbbVie Knocks Back Ablynx's Vobarilizumab In RA
A major setback for Ablynx as AbbVie decides not to exercise its opt-in for vobarilizumab in rheumatoid arthritis. Though the competitive landscape of biologics targeting IL-6 casts a shadow over its commercial prospects, Ablynx is determined to continue development.